Expanded Access for Relatlimab

Bristol-Myers Squibb (BMS)

Status

Treatments: Drug: Relatlimab

Study type: Expanded Access

Funder types: Industry

Identifiers

NCT05170659

CA209-64R

Details and patient eligibility

About

This is an expanded access designed to provide access to Relatlimab for eligible participants.

Sex

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria